1. Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues
FOXM1
p value
parameter
N=48
<10
>10, <50
>50, <100
>100, <200
>200
tissue
normal 8
8 (100%)
p=0.0003
cancer 40
5 (12.5%)
10 (25%)
12 (30%)
13 (32.5%)
Stage
1 and 2 17
2 (11.8%)
5 (29.4%)
8 (47.1%) NS
3 and 4 23
3 (13.0%)
8 (34.8%)
7 (30.4%)
5 (21.7%)
Differentiation 36
well 1
1 (100%)
moderate 13
1 (7.7%)
4 (30.8%)
5 (38.5%)
3 (23.1%)
poor 22
3 (13.6%
5 (22.7%)
4 (18.2%)
10 (45.5%)
Histology
serous 30
3 (10%)
9 (30%)
8 (26.7%)
10 (33.3%)
endometrioid 5
1 (20%)
3 (60%)
Serous-Endometriod 3
1 (33.3%)
2 (66.7%)
Mucinous
Clear cell

2. Supplemental Figure 2: Five HGS-OVCA patients clinical features
Age
Stage
Histology
Initial treatment
Platinum
status
Comments #1 74
IV-eff.
Primary peritoneal serous
Initial cytoreduction surgery
IV carbo/tax x 6 cycles
Platinum resistant
-Multidrug resistant sample obtained at progression after 4 lines of chemotherapy #2 66
Platinum refractory
-Sample taken at progression after 5th cycle of initial chemotherapy
-Died 4 months after initial diagnosis #3 64
IV-liver
Ovarian serous
Neoadjuvant carbo/tax x 3
Interval cytoreduction surgery
Adjuvant carbo/tax x2
-Sample taken at time of interval debulking with partial response.
--After surgery liver mets grew and pt died 10 months after dx. #4 65
IIIC
Debulking surgery
IVcarbo/tax/bev x6, maintenance
-Sample taken at initial surgery
-Progressed at 6 months after completion of chemotherapy #5 80
IV carbo/tax x 3 cycles
Unknown
-Sample from initial surgery prior to chemo
-Transfer of care to outside facility after 3rd cycle of chemo and no further clinical data available